Foresight Biotech & Health Extension Meeting sponsored by 100 Plus Capital.
Program & apply to join: https://foresight.org/biotech-health-extension-program/
Jennifer Garrison, Buck Institute.
Reframing Health and Aging through the Lens of Reproduct.
Brain-age (BA) estimates based on deep learning are increasingly used as neuroimaging biomarker for brain health; however, the underlying neural features have remained unclear. We combined ensembles of convolutional neural networks with Layer-wise Relevance Propagation (LRP) to detect which brain features contribute to BA. Trained on magnetic resonance imaging (MRI) data of a population-based study (n = 2,637, 18–82 years), our models estimated age accurately based on single and multiple modalities, regionally restricted and whole-brain images (mean absolute errors 3.37–3.86 years). We find that BA estimates capture ageing at both small and large-scale changes, revealing gross enlargements of ventricles and subarachnoid spaces, as well as white matter lesions, and atrophies that appear throughout the brain. Divergence from expected ageing reflected cardiovascular risk factors and accelerated ageing was more pronounced in the frontal lobe. Applying LRP, our study demonstrates how superior deep learning models detect brain-ageing in healthy and at-risk individuals throughout adulthood.
Researchers have just discovered a unique and novel intelligence property of hackmanite called gamma exposure memory. The mineral could be used in radiation detection applications.
CHICAGO, Sept 30 (Reuters) — Clear evidence this week that Eisai (4523.T) and Biogen’s (BIIB.O) drug lecanemab slows cognitive decline in early stage dementia has galvanized efforts among Alzheimer’s researchers toward a tantalizing goal — preventing dementia even before symptoms start.
Lecanemab is an antibody that targets and removes toxic clumps of a protein called amyloid beta that accumulate in the brains of patients with Alzheimer’s. Results from the companies’ 1,800-patient trial released on Tuesday showed convincingly that doing so also slows the advance of the mind-robbing disease.
In volunteers with mild cognitive impairment and early stage dementia, the drug showed a 27% reduction in cognitive decline after 18 months compared with those who got a placebo.
James Dyson’s technology firm gave a record 10-figure dividend to his family holding company last year as the billionaire continues to build up his fortune outside his largest asset.
Dyson Holdings paid Weybourne Holdings £1 billion ($1.1 billion) in 2021, the biggest annual cash transfer ever for the UK entrepreneur’s investment group, according to registry filings. Weybourne is also set to receive at least £500 million more this year from a dividend declared in January by the closely held maker of bagless vacuum cleaners.
I just uploaded in my YouTube channel my latest videoclip.
It’s an excerpt of an interview made few days ago by Phil Newman, Editor-in-Chief of Longevity. Technology to Aubrey de Grey.
Voila! Europa’s topography reveals itself to NASA’s Juno mission. The moon will be visited by the Europa Clipper in the 2020s.
Researchers were successful in printing models of well-known structures from several nations.
The developments in the field of additive manufacturing continue unabated. This time, Stanford University’s new burst will bring further innovation to the industry.
Published in Science Advances on September 28, the results demonstrate that the novel process is much faster than the quickest high-resolution printing method currently available.
Finding definitive evidence for past primitive life in ancient Mars rock and soil samples may be well-nigh impossible, renowned geologist and astrobiologist Frances Westall told me at the recent Europlanet Science Congress (EPSC) in Granada, Spain. And she should know. Westall is someone who still claims the discovery of Earth’s oldest-known microfossils, dating back some 3.45-billion-years ago.
But it’s hard enough to identify primitive microfossils in Earth’s oldest rocks, much less from robotic samples taken on Mars. Thus, if we have a hard time identifying past life on Earth, what hope do we have of doing it with Mars samples?
“I think it’s going to be really difficult,” said Westall, a researcher at France’s Center for Molecular Biophysics in Orleans. “I can tell you, there’s going to be a lot of arguments about it.”
